Literature DB >> 12733612

Appraising the economic efficiency of cancer treatment: an exploratory analysis of lung cancer.

Thomas N Chirikos1.   

Abstract

This paper tests whether the measured cost-effectiveness of treating different subgroups of an incident population of lung cancer patients differs significantly and, by implication, whether the provision of care to these patients is tolerably efficient in economic terms. Data from administrative records and Registry follow-up on 544 non-small cell lung cancer patients diagnosed at a single NCI-designated Comprehensive Cancer Center are used to conduct the empirical analysis. The main results show statistically significant differences in cumulative costs and patient outcomes across subgroups differing by disease stage and treatment modality. These findings imply that the delivery of lung cancer care is inefficient. Substantive and methodological implications are discussed.

Entities:  

Mesh:

Year:  2003        PMID: 12733612     DOI: 10.1023/a:1023380918605

Source DB:  PubMed          Journal:  Health Care Manag Sci        ISSN: 1386-9620


  16 in total

1.  Predictors of Medicare costs in elderly beneficiaries with breast, colorectal, lung, or prostate cancer.

Authors:  L Penberthy; S M Retchin; M K McDonald; D K McClish; C E Desch; G F Riley; T J Smith; B E Hillner; C J Newschaffer
Journal:  Health Care Manag Sci       Date:  1999-07

Review 2.  Measuring comorbidity in older cancer patients.

Authors:  M Extermann
Journal:  Eur J Cancer       Date:  2000-03       Impact factor: 9.162

3.  Modelling programme costs in economic evaluation.

Authors:  P Fenn; A McGuire; M Backhouse; D Jones
Journal:  J Health Econ       Date:  1996-02       Impact factor: 3.883

Review 4.  Quality of life assessment for cost/utility studies in cancer.

Authors:  R M Kaplan
Journal:  Cancer Treat Rev       Date:  1993       Impact factor: 12.111

5.  Costs of care associated with non-small-cell lung cancer in a commercially insured cohort.

Authors:  B E Hillner; M K McDonald; C E Desch; T J Smith; L T Penberthy; P Maddox; S M Retchin
Journal:  J Clin Oncol       Date:  1998-04       Impact factor: 44.544

Review 6.  Is chemotherapy for metastatic non-small cell lung cancer "worth it"?

Authors:  J C Ruckdeschel
Journal:  J Clin Oncol       Date:  1990-08       Impact factor: 44.544

Review 7.  Beyond survival: economic analyses of chemotherapy in advanced, inoperable NSCLC.

Authors:  D Mather; S D Sullivan; T V Parasuraman
Journal:  Oncology (Williston Park)       Date:  1998-02       Impact factor: 2.990

8.  Are we ready to use cost-effectiveness analysis in health care decision-making? A health services research challenge for clinicians, patients, health care systems, and public policy.

Authors:  E J Power; J M Eisenberg
Journal:  Med Care       Date:  1998-05       Impact factor: 2.983

Review 9.  Economic considerations in the care of lung cancer patients.

Authors:  C E Desch; B E Hillner; T J Smith
Journal:  Curr Opin Oncol       Date:  1996-03       Impact factor: 3.645

Review 10.  Economic issues in lung cancer: a review.

Authors:  P J Goodwin; F A Shepherd
Journal:  J Clin Oncol       Date:  1998-12       Impact factor: 44.544

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.